David Yaden

As psychedelic treatments approach potential FDA approval, psychiatrists need to be ready for patients’ questions.

New paper in JME Practical Bioethics: Katherine Cheung @katherinecheung.bsky.social, Edward Jacobs, and David Yaden @existwell.bsky.social review the ethics of psychedelic clinical trials and flag key concerns to resolve as psychedelics move toward real-world care. jmepb.bmj.com/content/2/4/...

Join us Wednesday, October 28, 2026 at 4:30pm ET for the Psychedelic Archives Project guest speaker series, featuring PhD Candidate David Wennberg, presenting “Self-Transcendence Beyond Ego Dissolution and Ego Death”. Join on this Zoom link: jhubluejays.zoom.us/j/92622903856

A comprehensive review of bioethical progress and need for further work on psychedelic research and potential clinical applications in screening, informed consent, dosing, follow-up, & more. Work led by @katherinecheung.bsky.social w/ @eddietalksdrugs.bsky.social & me jmepb.bmj.com/content/2/4/...

Psychedelics are such a common subject of discussion in medical and clinical contexts, that an understanding of the state of science is useful for any clinician. Here is a way to learn about psychedelic science and medicine:

Psychedelics are a common subject in medical and clinical contexts these days. This CME course provides an overview of the scientific state of the evidence. It is led by clinicians and scientists at @jhpsychedelics.bsky.social and one of the most efficient ways to get a sense for the field:

Amazing recognition for a remarkable advancement that has fueled modern neuroscience. Congrats to all!

What should clinicians know about psychedelic-assisted treatments? Learn from our experts and earn 6.5 CME/CE credits! 🔗 ⬇️ Fri, Oct. 9th | Online | 8:45am-4:30pm ET hopkinscme.cloud-cme.com/course/cours...

What should clinicians know about psychedelic-assisted treatments? Join our online CME/CE course for an evidence-based introduction to psychedelic medicine covering patient engagement, emerging research, and the future of psychedelic-assisted care. Register: hopkinscme.cloud-cme.com/course/cours...

Check out HOPE website with some resources here: hope-psychedelicethics.com Contact Associate Director Dr. Eddie Jacobs for more information @eddietalksdrugs.bsky.social

Support open-access research in psychological science – join the PsyArXiv Moderation team! 🧑‍🏫Moderator training is provided 🕰️Commitment: ~2 hours a month 📝Checking submissions for relevance, scope, and appropriate metadata 🌐Moderation work can be done asynchronously buff.ly/6TlgL7Q

Apply for @snfagora.bsky.social 's Postdoctoral Fellowship by November 5. See details here! snfagora.jhu.edu/fellowships-...

If you had to guess whether someone’s a philosopher, what’d be more predictive? Their decisions about thought experiments? Or their scores on assessments of neurodivergent traits? In more than 1000 people, the measures of #autistic (and other traits) were more predictive:

New paper – Validating and Creating a Short-Form of the Persisting Effects Questionnaire: A Measure of Positive and Negative Outcomes from Psychedelic Experiences

Eddie Jacobs PhD representing TheYadenLab, @jhpsychedelics.bsky.social, HOPE––and I think the consensus of many psychedelic scientists––at @fda.gov Any clinical application of psychedelics should, at least initially, use safeguards based on the clinical trial context until data can be gathered.

Representing Dr. David Yaden's (@existwell.bsky.social) lab at the CPCR & Hub at Oxford for Psychedelic Ethics (HOPE) — see Postdoc Eddie Jacobs, PhD from the FDA public hearing this week on the importance of safeguards based on standardized evidence on psychedelic treatments in clinical trials.

In clinical trials, these risks can be much lower due to screening, medical oversight, and controlled environments, but they are not zero. At Johns Hopkins CPCR, we try to share a reminder about risks every year. Promising clinical signals deserve careful science, not hype. youtu.be/uhQj9FgGIwc

Philosopher @nathansen.bsky.social has created a website that uses AI to take people through a Socratic dialogue about a philosophical thought experiment I gave it a try. In my opinion, it really does help users think through these questions www.ux-phi.com/experiments

Join the Psychedelic Archives Project guest speaker series with Dr. Charles Nichols this Wednesday through the zoom link, no sign up is required. jhubluejays.zoom.us/j/92622903856

Many of you will know the famous finding from @existwell.bsky.social and Derek Anderson: Philosophers' views on philosophical questions are not predicted by their personality traits But why not? I asked Anderson about this, and he had a very intriguing suggestion philarchive.org/rec/YADTPO-2

Interesting discussion prompted by @xphilosopher.bsky.social & @androidson.bsky.social on our study correlating philosophical views with psychological traits in philosophers: when philosophers indicate they “accept” a view (eg on PhilPapers survey), do they believe it or just defend it? Thoughts?

In some existing work, participants are explicitly asked whether their views have some hallmark properties of belief psycnet.apa.org/record/2026-... www.sciencedirect.com/science/arti... Participants sometimes openly acknowledge that they don't – which makes this seem like a workable strategy

For what it’s worth, I found some big five personality traits *did* correlate with certain philosophical views (above and beyond other demographic and cognitive factors, N > 700): doi.org/10.1007/s131... 🔓 philarchive.org/rec/BYRGMD

Dr. Charles Nichols joins us for the Psychedelic Archives Project guest speaker series, presenting “Psychedelic Use in Preconquest Mesoamerica: Probably Not What You’ve Been Told”, on Wednesday, September 16, 2026, at 4:30pm ET. Join on this Zoom link: jhubluejays.zoom.us/j/92622903856

Excited to share our new paper in Psychopharmacology: A pilot study comparing high-dose oral Δ9-THC, psilocybin, and placebo under the same set and setting used in psychedelic clinical trials. @jhpsychedelics.bsky.social 🧵 link.springer.com/article/10.1... 1/n

If you are doing something morally bad, people think two things: - that you can still be happy at this specific moment (see figure on left) - that in some larger way, you are not happy (see figure on right)

"Are you happy?" New research on two ways to understand this question: - as a question about how you feel right now, in this moment - as a question about the overall state of your life These two understandings turn out to be radically different www.sciencedirect.com/science/arti...

Great article in Scientific American on the Hopkins Post Psychedelic Difficulties Clinic! www.scientificamerican.com/article/firs...

Is it possible to change belief in free will with a quick manipulation? Answer seems to be: There is only an effect if you measure free will belief *immediately* after the manipulation… no effect if you measure free will belief even *a few minutes later* www.sciencedirect.com/science/arti...

Dr. Azin Bekhrad, co-founder and psychiatrist at the Johns Hopkins Clinic for Post-Psychedelic Difficulties, spoke with Scientific American on the first year of the clinic: www.scientificamerican.com/article/firs...

Great article in Scientific American on the Hopkins Post Psychedelic Difficulties Clinic! www.scientificamerican.com/article/firs...

Happening now!

What does psychedelic science have to learn from social sciences and humanities? We were concerned about reinventing the wheel, but now also about importing historical baggage through outdated theories and under-validated measures. Book event Wednesday in Washington, DC + Zoom

What should psychedelic science take - and not take - from other disciplines? Join us in celebrating the book launch of The Oxford Handbook of Psychedelic, Religious, Spiritual, and Mystical Experiences on Wed, Aug 5th from 10am-2pm ET. Attend in-person in Washington DC or virtually on Zoom.

Included in the book and discussion - are the terms that constitute the title of this book even useful?